PubMed Journals Articles About "Karus Therapeutics Ltd" RSS

13:40 EDT 3rd April 2020 | BioPortfolio

Karus Therapeutics Ltd PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Karus Therapeutics Ltd articles that have been published worldwide.

More Information about "Karus Therapeutics Ltd" on BioPortfolio

We have published hundreds of Karus Therapeutics Ltd news stories on BioPortfolio along with dozens of Karus Therapeutics Ltd Clinical Trials and PubMed Articles about Karus Therapeutics Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Karus Therapeutics Ltd Companies in our database. You can also find out about relevant Karus Therapeutics Ltd Drugs and Medications on this site too.

Showing "Karus Therapeutics" PubMed Articles 1–25 of 1,500+

Digital Therapeutics: Emerging New Therapy for Neurologic Deficits after Stroke.

Digital therapeutics is an evidence-based intervention using high-quality software, with the sole purpose of treatment. As many healthcare systems are encountering high demands of quality outcomes, the need for digital therapeutics is gradually increasing in the clinical field. We conducted review of the implications of digital therapeutics in the treatment of neurological deficits for stroke patients. The implications of digital therapeutics have been discussed in four domains: cognition, speech and aphasi...

Local treatment of infectious and noninfectious intermediate, posterior, and panuveitis: current concepts and emerging therapeutics.

Local therapeutics play an important role in the management of infectious and noninfectious uveitis (NIU) as well as certain masquerade syndromes. This review highlights the established therapeutics and those under investigation for the management of uveitis.

Measurement of mRNA therapeutics: method development and validation challenges.

The progression of chemically modified mRNA therapeutics through development pipelines is accelerating for many disease indications and the need to assess these analytes is becoming more routine for the pharmaceutical industry and contract research organizations. This article describes some of the challenges and strategies for performing regulated bioanalysis of modified mRNA therapeutics by comparing the two main analytical approaches - quantitative reverse transcription PCR and branched DNA.

Dr E. Keith Borden: Inaugural President of the Canadian Association for Population Therapeutics.

Pharmacovigilance 2030: Invited Commentary for the January 2020 "Futures" Edition of Clinical Pharmacology and Therapeutics.

Metabolism: A Burning Opioid Issue in Obesity Therapeutics.

Food restriction triggers a lowering in body temperature. A new study now provides a mechanism for this process that relies on opioid signaling in the hypothalamus. These observations suggest potential new therapeutics for obesity.

Re: "ISOPT Clinical Hot Topic Panel Discussion on Cornea Anterior Segment Disease" by Asbell et al. ( 2019;35:447-456).

Targeting angiotensinogen with RNA-based therapeutics.

To summarize all available data on targeting angiotensinogen with RNA-based therapeutics as a new tool to combat cardiovascular diseases.

Correction to: by Shrestha, A., Allen, B.N., Wiley, L.A. Tucker, B.A., and Worthington, K.S. J Ocul Pharmacol Ther 2020;36(1):42-55. DOI: 10.1089/jop.2018.0146.

Response to McMonnies and Young Re: "ISOPT Clinical Hot Topic Panel Discussion on Cornea Anterior Segment Disease" by Asbell et al. ( 2019;35:447-456).

From Engineered Tissues and Microfludics to Human Eyes-On-A-Chip.

Correction to: , by Blumenthal, E.Z, Cordeiro, M.F., Schmetterer, L. Verbin, H.L., and Harris, A. J Ocul Pharmacol Ther 2019;35(8):441-446. DOI: 10.1089/jop.2019.0004.

Eyes on New Product Development.

ISOPT Special Issue.

Eyes on New Product Development.

Medical therapeutics: mortality effects, uncertainty, and informed consent.

Many drugs used in medical therapeutics are able to save human lives. Unfortunately, many such drugs have also led to the death of patients. This fact raises important issues discussed in light of a number of cases taken from cardiovascular therapeutics. Medical therapeutics currently includes a vast number of different types of interventions, including drugs, devices, surgery, and diets. In what regards drugs, we currently use molecules with profound influences on the human body-some of which leading occas...

ISOPT Hot Topic Panel Discussion on Glaucoma.

As part of the 14th International Symposium on Ocular and Pharmacological Therapeutics, a unique panel was gathered to discuss two cardinal questions related to the treatment of glaucoma, peeking into the future: (1) What shape and form will glaucoma medical treatment have five and fifteen years from today, and (2) Will personalized medicine be commonly used five years from now. For each of the questions, we assigned an "optimist" and "pessimist" who provided the assigned point of view, for a total of 4 dis...

Rhenium-based complexes and in vivo testing: A brief history.

The success of metal-based anticancer therapeutics in the treatment of cancer is best exemplified by cisplatin. Currently used in 32 / 78 cancer regimens, the use for metal-based therapeutics has a clear role in cancer therapy. Despite this, metal-based therapeutics are not without drawbacks, with issues such as toxic side effects and the development of resistance mechanisms. This has led to investigations of other metal-based therapeutics such as auranofin, a gold-based drug candidate as well as ruthenium-...

Dig & Delve into Protein Based Nanoformulations.

Past few decades have emerged as the era of nanotechnology worldwide leading to an extensive research in pharmaceutical science as well as other fields. Nanoformulations have shown a promising future in therapeutics and theronostics. Protein based nanoformulations attracting attention in research as it can be used as therapeutics as well as carrier. Carrier based protein nanoformulatios are capable of accommodating range of therapeutics such as dyes, drugs, contrast agents and inorganic nanoclusters makings...

Optimizing COVID-19 candidate therapeutics: Thinking Without Borders.

This commentary seeks to share some key insights relevant to optimizing COVID-19 candidate therapeutics that were learned from attempts to optimize anti-infective posology in settings where quality and timely availability of data is challenging, with particular focus on influenza, including experiences from H5N1 and pH1N1 outbreaks.

American Society for Clinical Pharmacology and Therapeutics.

Small molecule therapeutics to treat the β-globinopathies.

The current review focuses on recent insights into the development of small molecule therapeutics to treat the β-globinopathies.

A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.

Although several experimental therapeutics for Ebola virus disease (EVD) have been developed, the safety and efficacy of the most promising therapies need to be assessed in the context of a randomized, controlled trial.

Antibodies against polyethylene glycol in human blood: A literature review.

Polyethylene glycol (PEG) conjugation, i.e. PEGylation, is a successful strategy to improve the pharmacokinetics and pharmacodynamics of biopharmaceuticals. In the past few decades, PEGylation technology has developed tremendously, and >15 PEGylated therapeutics have been brought to market, with more in development. However, the widely accepted assumption that PEG would have no antigenicity or immunogenicity is increasingly challenged with popularization of PEGylation technique. Although PEGylation indeed r...

Clinical Pharmacology & Therapeutics 2030.

Quick Search